HK1145290A1 - Oxidized avidin with high residency time in the treated tissues - Google Patents

Oxidized avidin with high residency time in the treated tissues

Info

Publication number
HK1145290A1
HK1145290A1 HK10111803.2A HK10111803A HK1145290A1 HK 1145290 A1 HK1145290 A1 HK 1145290A1 HK 10111803 A HK10111803 A HK 10111803A HK 1145290 A1 HK1145290 A1 HK 1145290A1
Authority
HK
Hong Kong
Prior art keywords
avidin
oxidation
avidins
treated tissues
periodate
Prior art date
Application number
HK10111803.2A
Other languages
English (en)
Inventor
Santis Rita De
Carlo Antonio Nuzzolo
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of HK1145290A1 publication Critical patent/HK1145290A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10111803.2A 2007-08-02 2010-12-16 Oxidized avidin with high residency time in the treated tissues HK1145290A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07113733 2007-08-02
EP08157473 2008-06-03
PCT/EP2008/059260 WO2009016031A1 (en) 2007-08-02 2008-07-16 Oxidized avidin with high residency time in the treated tissues

Publications (1)

Publication Number Publication Date
HK1145290A1 true HK1145290A1 (en) 2011-04-15

Family

ID=39734214

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111803.2A HK1145290A1 (en) 2007-08-02 2010-12-16 Oxidized avidin with high residency time in the treated tissues

Country Status (26)

Country Link
US (1) US8562947B2 (pt)
EP (1) EP2185203B1 (pt)
JP (1) JP5577248B2 (pt)
KR (1) KR101544628B1 (pt)
CN (1) CN101772353B (pt)
AR (1) AR067771A1 (pt)
AU (1) AU2008281901B2 (pt)
BR (1) BRPI0815050B8 (pt)
CA (1) CA2694391C (pt)
DK (1) DK2185203T3 (pt)
EA (1) EA017017B1 (pt)
ES (1) ES2625815T3 (pt)
HK (1) HK1145290A1 (pt)
HR (1) HRP20170735T1 (pt)
HU (1) HUE032093T2 (pt)
IL (1) IL203321A (pt)
LT (1) LT2185203T (pt)
MX (1) MX2010001302A (pt)
MY (1) MY155347A (pt)
NZ (1) NZ582711A (pt)
PL (1) PL2185203T3 (pt)
PT (1) PT2185203T (pt)
SG (1) SG183076A1 (pt)
SI (1) SI2185203T1 (pt)
TW (1) TWI441650B (pt)
WO (1) WO2009016031A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2591524C2 (ru) * 2010-12-28 2016-07-20 Джапан Тобакко Инк. Модифицированный тамавидин
ES2729549T3 (es) 2011-08-02 2019-11-04 Alfasigma Spa Composición farmacéutica de avidina oxidada adecuada para la inhalación
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
JP2016511747A (ja) 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子表面結合に基づく薬物の組織への送達
EP3316871A4 (en) 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
US20200179530A1 (en) * 2016-05-19 2020-06-11 University Of Miami Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells
CN112703401A (zh) * 2018-09-25 2021-04-23 美国西门子医学诊断股份有限公司 用于从使用缀合的分子阱的测定除去生物素干扰的方法和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433343D1 (de) * 1993-12-07 2003-12-24 Neorx Corp Pretargeting verfahren und mitteln
US5716594A (en) * 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
US8021667B2 (en) * 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US6632929B1 (en) * 1998-11-10 2003-10-14 Yeda Research And Development Co. Ltd Avidin derivatives and uses thereof
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US20040101901A1 (en) * 2002-11-27 2004-05-27 Piotr Tabaczewski Novel lipophilic complexes for insertion of receptors into lipid membranes
ITRM20030196A1 (it) * 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento

Also Published As

Publication number Publication date
AR067771A1 (es) 2009-10-21
IL203321A (en) 2014-05-28
KR20100051696A (ko) 2010-05-17
EA017017B1 (ru) 2012-09-28
HUE032093T2 (en) 2017-08-28
PL2185203T3 (pl) 2017-08-31
JP2010535166A (ja) 2010-11-18
CN101772353A (zh) 2010-07-07
EA201070216A1 (ru) 2010-08-30
TWI441650B (zh) 2014-06-21
JP5577248B2 (ja) 2014-08-20
AU2008281901B2 (en) 2013-08-15
US8562947B2 (en) 2013-10-22
CA2694391C (en) 2019-02-26
SG183076A1 (en) 2012-08-30
HRP20170735T1 (hr) 2017-07-28
BRPI0815050B1 (pt) 2020-01-28
PT2185203T (pt) 2017-06-02
KR101544628B1 (ko) 2015-08-17
CA2694391A1 (en) 2009-02-05
US20100239497A1 (en) 2010-09-23
EP2185203B1 (en) 2017-02-22
AU2008281901A1 (en) 2009-02-05
NZ582711A (en) 2011-10-28
TW200920403A (en) 2009-05-16
CN101772353B (zh) 2013-03-06
ES2625815T3 (es) 2017-07-20
BRPI0815050B8 (pt) 2021-05-25
LT2185203T (lt) 2017-06-12
DK2185203T3 (da) 2017-06-06
MY155347A (en) 2015-10-15
BRPI0815050A2 (pt) 2015-02-10
MX2010001302A (es) 2010-03-01
EP2185203A1 (en) 2010-05-19
WO2009016031A1 (en) 2009-02-05
BRPI0815050A8 (pt) 2017-12-26
SI2185203T1 (sl) 2017-07-31

Similar Documents

Publication Publication Date Title
HK1145290A1 (en) Oxidized avidin with high residency time in the treated tissues
WO2005005601A3 (en) Compositions and methods for treating and diagnosing cancer
MXPA06012500A (es) Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo.
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
PL2484365T3 (pl) Kompozycje i sposoby leczenia chorób neowaskularnych
WO2006014729A3 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
WO2007022470A3 (en) Methods and compositions for treating neurological disease
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
SG166672A1 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
AU2002365365A1 (en) Metal complex compounds
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
WO2007098047A3 (en) Methods and compositions for the treatment of parkinson's disease
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
MXPA05013210A (es) Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
WO2005103034A8 (en) Novel piperidine substituted diaminothiazoles
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO2004087734A3 (en) Stq-peptides
TW200727904A (en) Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine
WO2004110377A3 (en) Porphyrins and metalloporphyrins for inhibiting heme iron uptake
ATE268773T1 (de) Morphinoide verbindungen
WO2005000250A3 (en) Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor
WO2004022104A3 (en) Foxp2 and uses thereof